Featured Articles
-
1 In 300 People In The U.S. Is Living With HIV. That’s Not Okay With Jeff Galvin.
2/12/2024
By modifying CD4 T cells using miRNA, Jeff Galvin’s company thinks it can deliver a functional cure for HIV. Here’s the ongoing story of Addimmune and its unique clinical strategy.
-
How To Address ESG Risks Arising From Antimicrobial Resistance
2/12/2024
Pharmaceutical companies must do more to mitigate the growing legal and environmental, social, and governance (ESG) risks around anti-microbial resistance. Experts at international law firm Freshfields offer tips for company leaders.
-
Dynavax’s Evolving Business Model
2/9/2024
Dynavax found a new revenue stream during COVID, and a way to grow market share in the absence of a market. Ryan Spencer describes the ups and downs, and his own journey to CEO role.
-
Where Are They Now? Ono Pharmaceuticals
2/5/2024
Ono Pharmaceuticals continues its quest to become a global biopharmaceutical company, after discovering and helping to launch one of the most successful cancer drugs, Opdivo, in the last decade.
-
The Ozempic Dilemma: What Makes A Dual Brand Approach Viable?
2/5/2024
When should a brand become two brands? Charles River Associates provide analyses and case studies of dual brands to elucidate the pros and cons.
-
Innovation From Animals And Evolution
2/1/2024
Insights gleaned from a variety of animal species, and a deeper understanding of evolution aided by artificial intelligence, could help bring a new wave of therapies to market.
-
Empress Builds Base for Small-Molecule Innovation
2/1/2024
Empress, launched by Flagship Pioneering, aims to harness AI and evolutionary biology to design the next generation of small molecule therapies.
-
Companies to Watch: Promontory Therapeutics
2/1/2024
A novel small molecule developer aims to shake up the solid tumor treatment landscape.
-
Gene Editing Versus Gene Therapy: Is There A Difference?
1/31/2024
This article navigates the nomenclature that underlies gene therapy and gene editing technologies and explores the latest advancements in genome medicine.
-
That Price Is WAC: Boehringer’s Push For Access To Humira Biosimilars
1/29/2024
Boehringer Ingelheim's biosimilar commercial brand leader explains the company's two-tier pricing approach with Cyltezo, an interchangeable Humira biosimilar, and what new FDA guidance on interchangeability means for patients and physicians.